Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall ...
Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Alkermes (ALKS) settling at $26.70, representing a -1.26% change from its previous close.
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical breakthr...
Alkermes (ALKS) Stock Dips While Market Gains: Key Facts
The latest trading day saw Alkermes (ALKS) settling at $26.94, representing a -0.41% change from its previous close.
Why Alkermes (ALKS) Could Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note
Alkermes (ALKS) closed the most recent trading day at $27.74, moving -1% from the previous trading session.
The 3 Most Undervalued Biotech Stocks to Buy in January
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biot...
Alkermes (ALKS) Outperforms Broader Market: What You Need to Know
Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.
Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.
3 Growth Stocks Set to Dominate the Decade
In the evolving stock market landscape, identifying growth stocks to buy that promise resilience and prosperity over the long haul is akin to finding treasures in a rough, dusty terrain. This artic...
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023.
Why Alkermes Stock Is Sinking Today
Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a clinical update announced on Monday.
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment.
Related Companies